Result of WRAP Retail Offer
Fundraise raised £4.2m gross proceeds via placing, subscription and retail offer at 17p per share.
- Total gross proceeds raised £4.2m
- WRAP Retail Offer proceeds £0.1m
- Issue price per share 17p
- Total new shares issued 24,704,836
- Total ordinary shares in issue post-admission 258,779,463
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
20 June 2025 - SkinBioTherapeutics plc (AIM:SBTX), a life science group focused on skin health, confirms, further to the announcements made on 16 June 2025, the overall results of its Fundraise at the Issue Price of 17 pence per share.
The Company has raised aggregate gross proceeds of approximately £0.1 million pursuant to the WRAP Retail Offer, alongside the previously announced Placing and Subscription. Accordingly, the Company will issue a total of 587,191 new Ordinary Shares at the Issue Price pursuant to the WRAP Retail Offer.
In total, the Placing and Subscription and the WRAP Retail Offer have raised gross proceeds of approximately £4.2 million for the Company, via the Placing and Subscription of 24,117,645 Placing and Subscription Shares and the 587,191 WRAP Retail Offer Shares.
Admission and Total Voting Rights
Application has been made for the Placing and Subscription Shares and the WRAP Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to become effective on or around 24 June 2025.
Upon Admission, the Company's issued ordinary share capital will consist of 258,779,463 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission, the total number of Ordinary Shares and voting rights in the Company will be 258,779,463. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 2:14 p.m. on 16 June 2025.
Investor presentation
Now that the Open Offer has been closed, SkinBioTherapeutics will organising a presentation for shareholders, via the Investor Meet Company platform, in the week commencing 30 June 2025. The presentation will be open to all existing and potential SkinBioTherapeutics shareholders.
Once the timing of the presentation has been finalised, investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet Company for free Here.
The Company's LEI is 213800YMQOCB23FX6I06.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.